CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers

On May 31, 2017, at the 2017 Annual General Meeting of
Shareholders (the Annual Meeting), the shareholders of CRISPR
Therapeutics AG (the Company) approved the amendment and
restatement of the CRISPR Therapeutics AG 2016 Stock Option and
Incentive Plan (the Amended Plan).

to the terms of the Amended Plan, the maximum number of shares
authorized for issuance thereunder was increased by 2,012,684
shares to 9,284,463 shares. If the Companys capital structure
changes because of a reorganization, recapitalization,
reclassification, stock dividend, stock split or similar event,
the number of shares that can be issued under the Amended Plan
will be appropriately adjusted. The Amended Plan permits the
award of stock options (both incentive and non-qualified
options), stock appreciation rights, restricted stock, restricted
stock units, unrestricted stock, performance shares and dividend
equivalent rights.

A detailed summary of the material features of the Amended Plan
is set forth in the Companys definitive proxy statement for the
Annual Meeting filed with the Securities and Exchange Commission
on April 18, 2017. That summary and the foregoing description are
qualified in their entirety by reference to the text of the
Amended Plan, which is filed as Exhibit 10.1 hereto and
incorporated herein by reference.

Item5.07. Submission of Matters to a Vote of Security
Holders.

The Annual Meeting of the Company was held on May31, 2017.
Proxies were solicited to the Companys proxy statement filed on
April18, 2017, with the Securities and Exchange Commission under
Section14(a) of the Securities Exchange Act of 1934, as amended.

The number of shares of the Company entitled to vote at the
Annual Meeting was 39,813,491common shares, par value CHF 0.03
per share (Common Shares). The number of Common Shares present or
represented by valid proxy at the Annual Meeting was 31,107,919,
representing 78.13% of the total Common Shares entitled to vote
at the Annual Meeting. Each Common Share was entitled to one vote
with respect to matters submitted to the Companys shareholders at
the Annual Meeting.

At the Annual Meeting, the Companys shareholders were asked (i)to
approve the annual report, the consolidated financial statements
and the statutory financial statements of the Company for the
year ended December31, 2016, (ii) to approve the appropriation of
financial results, (iii)to discharge of the members of the Board
of Directors and Executive Committee, (iv)to re-elect eight members of the
Companys Board of Directors, (v)to re-elect four members of the
Compensation Committee of the Board of Directors, (vi)to approve
the compensation for the Board of Directors and the Executive
Committee, (vii)to approve an increase in the conditional share
capital for employee benefit plans, (viii)to approve the Amended
Plan, (ix)to re-elect the independent
voting rights representative, (x)to re-elect Ernst Young LLP as
the Companys independent registered public accounting firm for
the year ending December 31, 2017 and (xi)to approve the change
of the Companys registered office from Basel, Switzerland to Zug,
Switzerland.